The China Alzheimer’s disease therapeutics market size stood at around USD XX billion in 2019 and is projected to reach USD 2.206 billion by 2028, exhibiting a CAGR of XX% during the forecast period.
The prevalence and the targeted customers for the Alzheimer’s are the elderly population of any nation. The National Aged Population Office has published research in the Future Trends of Population Aging in China, which predicted that, by 2020, 248 million aged people, accounting for 17.17% of the whole population, will reside in China, and that aged 80 years or above will amount to 30.67 million, occupying a share of 12.37% of the total aged population.
The increased prevalence of neurological disorder among the geriatric population is the major driving factor for the growth of Alzheimer’s drug market in china. Also, growing awareness as well as societal changes with respect to Alzheimer’s treatment and Knowledge about the innovative treatment is yet another factor promoting the growth of Alzheimer’s market in china. Advance R&D and technological advancements are promoting the growth of the therapeutics market in this segment.